{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T01:10:41Z","timestamp":1752282641237},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00108-024-01669-4","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T18:02:00Z","timestamp":1708365720000},"page":"334-339","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Arzneimittelinduzierte immunvermittelte Lebersch\u00e4digung","Drug-induced autoimmune-like liver injury"],"prefix":"10.1007","volume":"65","author":[{"given":"Sabine","family":"Weber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"issue":"6","key":"1669_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1136\/gutjnl-2016-313369","volume":"66","author":"GA Kullak-Ublick","year":"2017","unstructured":"Kullak-Ublick\u00a0GA, Andrade\u00a0RJ, Merz\u00a0M, End\u00a0P, Benesic\u00a0A, Gerbes\u00a0AL et\u00a0al (2017) Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 66(6):1154\u20131164","journal-title":"Gut"},{"issue":"7","key":"1669_CR2","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1053\/j.gastro.2015.02.050","volume":"148","author":"DS Goldberg","year":"2015","unstructured":"Goldberg\u00a0DS, Forde\u00a0KA, Carbonari\u00a0DM, Lewis\u00a0JD, Leidl\u00a0KB, Reddy\u00a0KR et\u00a0al (2015) Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. Gastroenterology 148(7):1353\u201361.e3","journal-title":"Gastroenterology"},{"issue":"7","key":"1669_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMra052270","volume":"354","author":"VJ Navarro","year":"2006","unstructured":"Navarro\u00a0VJ, Senior\u00a0JR (2006) Drug-related hepatotoxicity. N\u00a0Engl J Med 354(7):731\u2013739","journal-title":"N Engl J Med"},{"issue":"2","key":"1669_CR4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/hep4.1465","volume":"4","author":"P Shah","year":"2020","unstructured":"Shah\u00a0P, Sundaram\u00a0V, Bjornsson\u00a0E (2020) Biologic and checkpoint inhibitor-induced liver injury: a\u00a0systematic literature review. Hepatol Commun 4(2):172\u2013184","journal-title":"Hepatol Commun"},{"issue":"3","key":"1669_CR5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1056\/NEJMra1816149","volume":"381","author":"JH Hoofnagle","year":"2019","unstructured":"Hoofnagle\u00a0JH, Bjornsson\u00a0ES (2019) Drug-induced liver injury\u2014types and phenotypes. N\u00a0Engl J Med 381(3):264\u2013273","journal-title":"N Engl J Med"},{"issue":"6","key":"1669_CR6","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1002\/hep.20948","volume":"42","author":"AM Larson","year":"2005","unstructured":"Larson\u00a0AM, Polson\u00a0J, Fontana\u00a0RJ, Davern\u00a0TJ, Lalani\u00a0E, Hynan\u00a0LS et\u00a0al (2005) Acetaminophen-induced acute liver failure: results of a\u00a0United States multicenter, prospective study. Hepatology 42(6):1364\u20131372","journal-title":"Hepatology"},{"issue":"5","key":"1669_CR7","doi-asserted-by":"publisher","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","volume":"116","author":"NP Chalasani","year":"2021","unstructured":"Chalasani\u00a0NP, Maddur\u00a0H, Russo\u00a0MW, Wong\u00a0RJ, Reddy\u00a0KR, Practice Parameters Committee of the American College of Gastroenterology (2021) ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 116(5):878\u2013898","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"1669_CR8","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal\u00a0GP, Watkins\u00a0PB, Andrade\u00a0RJ, Larrey\u00a0D, Molokhia\u00a0M, Takikawa\u00a0H et\u00a0al (2011) Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 89(6):806\u2013815","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1669_CR9","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"European Association for the Study of the Liver","year":"2019","unstructured":"European Association for the Study of the Liver (2019) EASL clinical practice guidelines: drug-induced liver injury. J\u00a0Hepatol 70(6):1222\u20131261","journal-title":"J Hepatol"},{"issue":"11","key":"1669_CR10","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","volume":"46","author":"G Danan","year":"1993","unstructured":"Danan\u00a0G, Benichou\u00a0C (1993) Causality assessment of adverse reactions to drugs\u2014I. A\u00a0novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J\u00a0Clin Epidemiol 46(11):1323\u20131330","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"1669_CR11","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/hep.22442","volume":"48","author":"J Rochon","year":"2008","unstructured":"Rochon\u00a0J, Protiva\u00a0P, Seeff\u00a0LB, Fontana\u00a0RJ, Liangpunsakul\u00a0S, Watkins\u00a0PB et\u00a0al (2008) Reliability of the Roussel Uclaf causality assessment method for assessing causality in drug-induced liver injury. Hepatology 48(4):1175\u20131183","journal-title":"Hepatology"},{"key":"1669_CR12","doi-asserted-by":"publisher","unstructured":"Weber\u00a0S, Gerbes\u00a0AL (2022) Challenges and future of drug-induced liver injury research-laboratory tests. Int J Mol Sci 23(11). https:\/\/doi.org\/10.3390\/ijms23116049","DOI":"10.3390\/ijms23116049"},{"issue":"2","key":"1669_CR13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/liv.13584","volume":"38","author":"DE Kleiner","year":"2018","unstructured":"Kleiner\u00a0DE (2018) Histopathological challenges in suspected drug-induced liver injury. Liver Int 38(2):198\u2013209","journal-title":"Liver Int"},{"issue":"5","key":"1669_CR14","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","volume":"31","author":"F Alvarez","year":"1999","unstructured":"Alvarez\u00a0F, Berg\u00a0PA, Bianchi\u00a0FB, Bianchi\u00a0L, Burroughs\u00a0AK, Cancado\u00a0EL et\u00a0al (1999) International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J\u00a0Hepatol 31(5):929\u2013938","journal-title":"J Hepatol"},{"issue":"1","key":"1669_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes\u00a0EM, Zeniya\u00a0M, Czaja\u00a0AJ, Pares\u00a0A, Dalekos\u00a0GN, Krawitt\u00a0EL et\u00a0al (2008) Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48(1):169\u2013176","journal-title":"Hepatology"},{"issue":"3","key":"1669_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000511635","volume":"39","author":"S Weber","year":"2021","unstructured":"Weber\u00a0S, Benesic\u00a0A, Buchholtz\u00a0ML, Rotter\u00a0I, Gerbes\u00a0AL (2021) Antimitochondrial rather than antinuclear antibodies correlate with severe drug-induced liver injury. Dig Dis 39(3):275\u2013282","journal-title":"Dig Dis"},{"issue":"4","key":"1669_CR17","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","volume":"63","author":"European Association for the Study of the Liver","year":"2015","unstructured":"European Association for the Study of the Liver (2015) EASL clinical practice guidelines: autoimmune hepatitis. J\u00a0Hepatol 63(4):971\u20131004","journal-title":"J Hepatol"},{"issue":"1","key":"1669_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jhep.2012.09.009","volume":"58","author":"NM van Gerven","year":"2013","unstructured":"van Gerven\u00a0NM, Verwer\u00a0BJ, Witte\u00a0BI, van Hoek\u00a0B, Coenraad\u00a0MJ, van Erpecum\u00a0KJ et\u00a0al (2013) Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J\u00a0Hepatol 58(1):141\u2013147","journal-title":"J Hepatol"},{"issue":"6","key":"1669_CR19","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1002\/hep.23588","volume":"51","author":"E Bjornsson","year":"2010","unstructured":"Bjornsson\u00a0E, Talwalkar\u00a0J, Treeprasertsuk\u00a0S, Kamath\u00a0PS, Takahashi\u00a0N, Sanderson\u00a0S et\u00a0al (2010) Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 51(6):2040\u20132048","journal-title":"Hepatology"},{"issue":"10","key":"1669_CR20","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1111\/liv.14195","volume":"39","author":"S Weber","year":"2019","unstructured":"Weber\u00a0S, Benesic\u00a0A, Rotter\u00a0I, Gerbes\u00a0AL (2019) Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis. Liver Int 39(10):1906\u20131917","journal-title":"Liver Int"},{"issue":"3","key":"1669_CR21","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jhep.2023.04.033","volume":"79","author":"RJ Andrade","year":"2023","unstructured":"Andrade\u00a0RJ, Aithal\u00a0GP, de Boer\u00a0YS, Liberal\u00a0R, Gerbes\u00a0A, Regev\u00a0A et\u00a0al (2023) Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): an expert opinion meeting report. J\u00a0Hepatol 79(3):853\u2013866","journal-title":"J Hepatol"},{"issue":"6","key":"1669_CR22","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1002\/hep.26290","volume":"57","author":"JH Ngu","year":"2013","unstructured":"Ngu\u00a0JH, Gearry\u00a0RB, Frampton\u00a0CM, Stedman\u00a0CA (2013) Predictors of poor outcome in patients w ith autoimmune hepatitis: a\u00a0population-based study. Hepatology 57(6):2399\u20132406","journal-title":"Hepatology"},{"issue":"10","key":"1669_CR23","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.cgh.2017.05.027","volume":"15","author":"ES Bjornsson","year":"2017","unstructured":"Bjornsson\u00a0ES, Bergmann\u00a0O, Jonasson\u00a0JG, Grondal\u00a0G, Gudbjornsson\u00a0B, Olafsson\u00a0S (2017) Drug-induced autoimmune hepatitis: response to corticosteroids and lack of relapse after cessation of steroids. Clin Gastroenterol Hepatol 15(10):1635\u20131636","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"1669_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1159\/000528329","volume":"104","author":"S Weber","year":"2023","unstructured":"Weber\u00a0S, Gerbes\u00a0AL (2023) Relapse and need for extended Immunosuppression: novel features of drug-induced autoimmune hepatitis. Digestion 104(3):243\u2013248","journal-title":"Digestion"},{"key":"1669_CR25","doi-asserted-by":"publisher","first-page":"102514","DOI":"10.1016\/j.jaut.2020.102514","volume":"114","author":"A Regev","year":"2020","unstructured":"Regev\u00a0A, Avigan\u00a0MI, Kiazand\u00a0A, Vierling\u00a0JM, Lewis\u00a0JH, Omokaro\u00a0SO et\u00a0al (2020) Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. J\u00a0Autoimmun 114:102514","journal-title":"J Autoimmun"},{"issue":"8","key":"1669_CR26","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1111\/liv.14489","volume":"40","author":"M Riveiro-Barciela","year":"2020","unstructured":"Riveiro-Barciela\u00a0M, Barreira-Diaz\u00a0A, Vidal-Gonzalez\u00a0J, Munoz-Couselo\u00a0E, Martinez-Valle\u00a0F, Viladomiu\u00a0L et\u00a0al (2020) Immune-related hepatitis related to checkpoint inhibitors: clinical and prognostic factors. Liver Int 40(8):1906\u20131916","journal-title":"Liver Int"},{"issue":"4","key":"1669_CR27","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","volume":"160","author":"M Dougan","year":"2021","unstructured":"Dougan\u00a0M, Wang\u00a0Y, Rubio-Tapia\u00a0A, Lim\u00a0JK (2021) AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology 160(4):1384\u20131393","journal-title":"Gastroenterology"},{"issue":"10","key":"1669_CR28","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/j.jhepr.2023.100851","volume":"5","author":"E Atallah","year":"2023","unstructured":"Atallah\u00a0E, Welsh\u00a0SJ, O\u2019Carrigan\u00a0B, Oshaughnessy\u00a0A, Dolapo\u00a0I, Kerr\u00a0AS et\u00a0al (2023) Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: a\u00a010-year real-world retrospective cohort study. JHEP Rep 5(10):100851. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100851","journal-title":"JHEP Rep"},{"issue":"1","key":"1669_CR29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jhep.2021.07.024","volume":"76","author":"H Shroff","year":"2022","unstructured":"Shroff\u00a0H, Satapathy\u00a0SK, Crawford\u00a0JM, Todd\u00a0NJ, VanWagner\u00a0LB (2022) Liver injury following SARS-CoV\u20112 vaccination: a\u00a0multicenter case series. J\u00a0Hepatol 76(1):211\u2013214","journal-title":"J Hepatol"},{"issue":"3","key":"1669_CR30","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jhep.2022.03.040","volume":"77","author":"T Boettler","year":"2022","unstructured":"Boettler\u00a0T, Csernalabics\u00a0B, Salie\u00a0H, Luxenburger\u00a0H, Wischer\u00a0L, Salimi Alizei\u00a0E et\u00a0al (2022) SARS-CoV\u20112 vaccination can elicit a\u00a0CD8 T\u2011cell dominant hepatitis. J\u00a0Hepatol 77(3):653\u2013659","journal-title":"J Hepatol"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01669-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01669-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01669-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T11:03:01Z","timestamp":1711105381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01669-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1669"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01669-4","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,19]]},"assertion":[{"value":"25 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Weber gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}